MAM
Hockey India names Digital Latte as its social media agency
Mumbai: Hockey India has announced the signing of Digital Latte as its new digital media agency for the management of its social media requirements.
Digital Latte, a full-service creative digital agency, will be working towards presenting fresh digital ideas to push for engaging content on all social media platforms, and will also be using consumer insights to connect with the hockey fans in India and abroad, said the statement.
“We are delighted to partner with Digital Latte as our new social media agency. In the growing digital world, it is important to connect with your audience digitally, and Digital Latte’s growing reputation over the past decade has convinced us that it is the ideal agency for us to work towards that goal,” stated Hockey India president Gyanendro Ningombam.
Following the success of the Indian Men and Women’s Hockey Teams at the Olympic Games Tokyo 2020 where the Indian Men ended a 41-year medal drought with their bronze medal feat and the Women team’s historic fourth-place finish, Hockey India believes it is the right time to seize the popularity of the sport and engage with global fans with right digital messaging and promotion of the players across teams.
“Particularly after the Olympic success, Indian Hockey is gaining popularity not just in India but across the world and the sport’s digital presence is of paramount importance. We see this as an opportunity to further build the Hockey India brand and explore commercial opportunities for the future development of the sport,” Ningombam further said.
Commenting on the new association, Digital Latte founder and director Chintan Vora said, “Hockey is a sport of intrinsic value to our cultural and national identity in India. It is a great opportunity for Digital Latte to associate so closely with an organisation of national importance such as Hockey India.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
